1 Department of Pain, Tongji Medical College, Huazhong University of Science and Technology, The Central Hospital of Wuhan, Wuhan 430021, China.
2 Department of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, The Central Hospital of Wuhan, Wuhan 430021, China.
Exp Biol Med (Maywood). 2019 Jan;244(1):22-27. doi: 10.1177/1535370218823684. Epub 2019 Jan 12.
Critical limb ischemia (CLI) is a serious arterial obstruction, resulting in serious reduction of blood flow to the extremities. CLI is a symptomatic disorder and is frequently not diagnosed in time. This results in a high mortality and elevated risk of limb amputation. Serum or plasma biomarkers play important roles in disease prevention, diagnosis, and prognosis. Elevated plasma neutrophil-activating peptide-2 (NAP-2) was found independently associated with CLI, but not with T2DM. Plasma NAP-2 levels might be an early CLI diagnostic biomarker and might provide a novel target for CLI treatment.
严重肢体缺血（CLI）是一种严重的动脉阻塞，导致肢体血液流量严重减少。CLI 是一种有症状的疾病，通常不能及时诊断。这导致高死亡率和高截肢风险。血清或血浆生物标志物在疾病预防、诊断和预后中发挥着重要作用。研究发现，血浆中性粒细胞激活肽-2（NAP-2）水平升高与 CLI 独立相关，但与 T2DM 无关。血浆 NAP-2 水平可能是 CLI 的早期诊断生物标志物，也可能为 CLI 的治疗提供新的靶点。
